{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:36Z","timestamp":1753891236341,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This case report presents an instance of Tumor Necrosis Factor-<jats:italic>\u03b1<\/jats:italic> Inhibitor-induced psoriasis (TNFiIP), also known as paradoxical psoriasis, in a 30-year-old male with fistulizing Crohn\u2019s disease. The patient developed extensive erythematous and scaly lesions on the palms, lower limbs, ankles, and soles after 4\u202fmonths of adalimumab monotherapy. Histopathological analysis revealed a pattern of psoriasiform dermatitis with notable dermal neutrophil and eosinophil infiltration, distinguishing TNFiIP from idiopathic psoriasis. The patient\u2019s condition significantly improved following the transition from adalimumab to ustekinumab, which highlights the importance of alternative therapeutic strategies for patients who exhibit paradoxical reactions to TNF-<jats:italic>\u03b1<\/jats:italic> inhibitors.<\/jats:p>","DOI":"10.3389\/fmed.2024.1507524","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:21:32Z","timestamp":1737696092000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adalimumab induced psoriasis in Crohn\u2019s disease and treatment with ustekinumab: case report and special histopathological findings"],"prefix":"10.3389","volume":"11","author":[{"given":"Fang","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.cgh.2024.04.005","article-title":"Higher adalimumab concentration is associated with complete fistula healing in patients with perianal Fistulizing Crohn's disease","volume":"22","author":"Papamichael","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/14712598.2024.2316180","article-title":"Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies","volume":"24","author":"Tursi","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e2250075","DOI":"10.1002\/eji.202250075","article-title":"Interleukin-21 in autoimmune and inflammatory skin diseases","volume":"53","author":"Mesas-Fern\u00e1ndez","year":"2023","journal-title":"Eur J Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4049\/jimmunol.1901358","article-title":"TNF-\u03b1 regulates human Plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation","volume":"206","author":"Psarras","year":"2021","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2020.01.006","article-title":"Histologic comparison of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis and psoriasis vulgaris","volume":"83","author":"Hu","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","article-title":"Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists","volume":"39","author":"Hawryluk","year":"2012","journal-title":"J Cutan Pathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/jir.2016.0036","article-title":"Eosinophils regulate interferon alpha production in Plasmacytoid dendritic cells stimulated with components of neutrophil extracellular traps","volume":"37","author":"Skrzeczynska-Moncznik","year":"2017","journal-title":"J Interf Cytokine Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e14883","DOI":"10.1111\/dth.14883","article-title":"Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases","volume":"34","author":"Wu","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00296-018-4034-0","article-title":"Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy","volume":"38","author":"Benzaquen","year":"2018","journal-title":"Rheumatol Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1507524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:21:34Z","timestamp":1737696094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1507524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":13,"alternative-id":["10.3389\/fmed.2024.1507524"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1507524","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1507524"}}